中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
MeSH:(Prostatic Neoplasms, Castration-Resistant/mortality*)

1.Updated treatment of castration-resistant prostate cancer.

Song XU ; Zheng-Yu ZHANG

National Journal of Andrology 2014;20(12):1136-1140

2.Expression of SRD5A1 and its prognostic role in prostate cancer: Analysis based on the data-mining of ONCOMINE.

Bin XU ; Ning LIU ; Shu-Qiu CHEN ; Hua JIANG ; Li-Jie ZHANG ; Xiao-Wen ZHANG ; Yu YANG ; Guo-Zhu SHA ; Jing LIU ; Wei-Dong ZHU ; Ming CHEN

National Journal of Andrology 2016;22(9):771-776

3.Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods.

Ji-Li WANG ; Yan WANG ; Guo-Ping REN

Journal of Zhejiang University. Science. B 2020;21(3):246-255

5.Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.

Guo-Wen LIN ; Gao-Xiang LI ; Bo DAI ; Ding-Wei YE ; Yun-Yi KONG ; Yue WANG ; Yi-Jun SHEN

Asian Journal of Andrology 2019;21(2):131-136

6.Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.

Kyo Chul KOO ; Sang Un PARK ; Ki Hong KIM ; Koon Ho RHA ; Sung Joon HONG ; Seung Choul YANG ; Byung Ha CHUNG

Yonsei Medical Journal 2015;56(5):1206-1212

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO